Quitting Ozempic-Like Drugs May Double Heart Risk
By @sharedot · · 8 pages
- Health
- Glp 1
- Diabetes
- Cardiovascular Health
A study of 80,000 Italians found stopping GLP-1 drugs roughly doubled heart attack, stroke or death risk, though experts urge caution.
What happened
An international study published in The Lancet Regional Health — Europe followed more than 80,000 Italians with type 2 diabetes and no established cardiovascular disease across 301 diabetes clinics between 2004 and 2024.
Researchers led by Antonio Ceriello of IRCCS MultiMedica compared patients who stopped GLP-1 receptor agonists with those who kept taking them over four years, and observed sharply higher rates of heart attack, stroke and death among those who discontinued treatment.
Why it is surprising
The scale of the association startled even the lead author: about four in 100 people who stopped GLP-1 treatment had a heart attack, stroke or died from any cause, compared with about two in 100 who kept using the medication — nearly doubling the risk.
The Pharmacist reports that people who discontinued were more than four times as likely to die from any cause as persistent users, and that the findings held even though weight, blood pressure and blood sugar rose only modestly after stopping, which Ceriello said is 'not sufficient to fully explain the observed increase in risk.'
The evidence — and its limits
The authors theorise GLP-1 drugs may offer 'direct protection' to the cardiovascular system that is lost when treatment stops. But the study is observational and cannot prove causation.
Professor Naveed Sattar of the University of Glasgow told The Pharmacist the results 'should be interpreted as associations rather than evidence that stopping the medication directly causes higher cardiovascular or other health risks.'
ABC News reports Australian experts, including Clara Chow of the University of Sydney, note no data was collected on why people stopped — and that discontinuation 'is a marker of the fact that they're sick as opposed to a cause of their sickness.'
The stakes
About half a million Australians use GLP-1 receptor agonists each month, according to ABC News, and The Pharmacist reports 20–50% of patients stop therapy within the first year, citing side effects, cost and doubts about effectiveness.
The study also excluded tirzepatide (Mounjaro) and only a small number of participants used semaglutide (Ozempic and Wegovy), with most taking liraglutide or dulaglutide — leaving questions about how the findings apply to the most widely prescribed drugs today.
Related: protecting muscle on these drugs
The same day, The West Australian reported a University of Western Australia study in Nature Medicine finding that people on tirzepatide who lifted weights three times a week lost the same total weight as non-trainers but 25 per cent less lean tissue, and gained 10 per cent strength while non-exercisers lost 10 per cent.
Lead investigator Professor Danny Green said combining weight-loss therapy with resistance exercise 'improves overall health' and could extend healthspan.
What comes next
Experts agree the takeaway is not to quit abruptly. Brendon Neuen of Royal North Shore Hospital told ABC News that for people with chronic conditions a GLP-1 drug is helping, 'long-term treatment is important,' and anyone considering stopping should talk to a health professional first.
Researchers want more data on whether doses or frequency can be reduced safely, why patients discontinue, and whether gut or circadian interventions — as a separate UTHealth Houston study in iScience suggested for metabolic risk — can modifiably lower disease risk.
Neuen called this study 'one small piece of the puzzle.'